NASDAQ: AKBAAkebia Therapeutics Inc Stock
$2.07+0.01 (+0.49%)
Updated Apr 21, 2025
AKBA Price
$2.07
Fair Value Price
-$1.61
Market Cap
$489.00M
52 Week Low
$0.80
52 Week High
$2.89
P/E
-6.27x
P/B
-9.94x
P/S
2.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$160.18M
Earnings
-$69.41M
Gross Margin
60.6%
Operating Margin
-31.98%
Profit Margin
-43.3%
Debt to Equity
-5.49
Operating Cash Flow
-$41M
Beta
1.67
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
AKBA Overview
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKBA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AKBA
Ranked#87 of 462
Ranked#87 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important AKBA news, forecast changes, insider trades & much more!
AKBA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKBA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKBA ($2.07) is overvalued by 228.4% relative to our estimate of its Fair Value price of -$1.61 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AKBA ($2.07) is not significantly undervalued (228.4%) relative to our estimate of its Fair Value price of -$1.61 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AKBA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AKBA due diligence checks available for Premium users.
Valuation
AKBA fair value
Fair Value of AKBA stock based on Discounted Cash Flow (DCF)
Price
$2.07
Fair Value
-$1.61
Undervalued by
228.40%
AKBA ($2.07) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AKBA ($2.07) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AKBA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AKBA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.27x
Industry
-184.27x
Market
27.14x
AKBA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-9.94x
Industry
4.04x
AKBA's financial health
Profit margin
Revenue
$46.5M
Net Income
-$22.8M
Profit Margin
-49%
AKBA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AKBA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$220.7M
Liabilities
$269.9M
Debt to equity
-5.49
AKBA's short-term assets ($113.83M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKBA's long-term liabilities ($188.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKBA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKBA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5M
Investing
-$2.0k
Financing
$22.3M
AKBA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKBA vs Biotech Stocks
Akebia Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.